Azole resistance in Aspergillus species: promising therapeutic options

References

• Singh A, Sharma B, Mahto KK, et al. High-frequency direct detection of triazole resistance in Aspergillus fumigatus from patients with chronic pulmonary fungal diseases in India. J Fungi (Basel). 2020;6(2):67.
   Google Scholar
• Buil JB, Hagen F, Chowdhary A, et al. Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant Aspergillus fumigatus isolates. J Fungi (Basel). 2018;4(3):103.
   Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1–e38.
   PubMed Web of Science ®Google Scholar
• Resendiz Sharpe A, Lagrou K, Meis JF, et al. Triazole resistance surveillance in Aspergillus fumigatus. Med Mycol. 2018;56(suppl_1):83–92.
   PubMedGoogle Scholar
• Denning DW, Venkateshwarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;47:1364–1368.
   Google Scholar
• Chowdhary A, Kathuria S, Xu J, et al. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9(10):e1003633.
   PubMed Web of Science ®Google Scholar
• Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis. 2013;26(6):493–500.
   PubMed Web of Science ®Google Scholar
• Snelders E, Camps SM, Karawajczyk A, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One. 2012;7(3):e31801.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Snelders E, Kema GHJ, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009;9(12):789–795.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Ananda-Rajah M, Andes D, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. In: Drug Resist Updat. 2015;21-22:30–40.
   PubMed Web of Science ®Google Scholar
• Snelders E, Van Der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5(11):e219.
   PubMed Web of Science ®Google Scholar
• Abdolrasouli A, Petrou MA, Park H, et al. Surveillance for azole-resistant Aspergillus fumigatus in a centralized diagnostic mycology service, London, United Kingdom, 1998–2017. Front Microbiol. 2018;9:2234.
   PubMed Web of Science ®Google Scholar
• Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65(10):2116–2118.
   PubMed Web of Science ®Google Scholar
• Van Der Linden JW, Arendrup MC, Warris A, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis. 2015;21(6):1041–1044.
   PubMed Web of Science ®Google Scholar
• Vermeulen E, Maertens J, De Bel A, et al. Nationwide surveillance of azole resistance in Aspergillus diseases. Antimicrob Agents Chemother. 2015;59(8):4569–4576.
   PubMed Web of Science ®Google Scholar
• Morio F, Aubin GG, Danner-Boucher I, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother. 2012;67(8):1870–1873.
   PubMed Web of Science ®Google Scholar
• Alanio A, Sitterle E, Liance M, et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother. 2011;66(2):371–374.
   PubMed Web of Science ®Google Scholar
• Choukri F, Botterel F, Sitterle E, et al. Prospective evaluation of azole resistance in Aspergillus fumigatus clinical isolates in France. Med Mycol. 2015;53(6):593–596.
   PubMed Web of Science ®Google Scholar
• Seufert R, Sedlacek L, Kahl B, et al. Prevalence and characterization of azole-resistant Aspergillus fumigatus in patients with cystic fibrosis: a prospective multicentre study in Germany. J Antimicrob Chemother. 2018;73(8):2047–2053.
   PubMed Web of Science ®Google Scholar
• Steinmann J, Hamprecht A, Vehreschild MJGT, et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015;70(5):1522–1526.
   PubMed Web of Science ®Google Scholar
• Prigitano A, Esposto MC, Biffi A, et al. Triazole resistance in Aspergillus fumigatus isolates from patients with cystic fibrosis in Italy. J Cyst Fibros. 2017;16(1):64–69.
   PubMed Web of Science ®Google Scholar
• Prigitano A, Esposto MC, Grancini A, et al. Prospective multicentre study on azole resistance in Aspergillus isolates from surveillance cultures in haematological patients in Italy. J Glob Antimicrob Resist. 2020;22:231–237.
   PubMed Web of Science ®Google Scholar
• Escribano P, Rodríguez-Sánchez B, Díaz-García J, et al. Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain [published online ahead of print, 2020 Oct 1]. Clin Microbiol Infect. 2020. DOI:https://doi.org/10.1016/j.cmi.2020.09.042.
   Google Scholar
• Alastruey-Izquierdo A, Alcazar-Fuoli L, Rivero-Menéndez O, et al. Molecular identification and susceptibility testing of molds isolated in a prospective surveillance of triazole resistance in Spain (FILPOP2 study). Antimicrob Agents Chemother. 2018;62:e00358–18.
   PubMed Web of Science ®Google Scholar
• Pham CD, Reiss E, Hagen F, et al. Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013. Emerg Infect Dis. 2014;20(9):1498–1503.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Gil VG, Gutierrez F, et al. First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus Isolates in the United States. J Clin Microbiol. 2016;54(1):168–171.
   PubMed Web of Science ®Google Scholar
• Pontes L, Beraquet CAG, Arai T, et al. Aspergillus fumigatus clinical isolates carrying CYP51A with TR34/L98H/S297T/F495I substitutions detected after four-year retrospective azole resistance screening in Brazil. Antimicrob Agents Chemother. 2020;64:e02059–19.
   PubMed Web of Science ®Google Scholar
• Beer KD, Farnon EC, Jain S, et al. Multidrug-resistant Aspergillus fumigatus carrying mutations linked to environmental fungicide exposure — three states, 2010–2017. MMWR. 2018;67:1064–1067.
   PubMed Web of Science ®Google Scholar
• Hurst SF, Berkow EL, Stevenson KL, et al. Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA. J Antimicrob Chemother. 2017;72(9):2443–2446.
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Frade JP, Etienne KA, et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother. 2011;55(9):4465–4468.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Meis JF. Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S436–S44.
   PubMedGoogle Scholar
• Jung IY, Lee YJ, Shim HS, et al. Identification of fungal species and detection of azole-resistance mutations in the Aspergillus fumigatus cyp51A gene at a South Korean Hospital. Yonsei Med J. 2020;61(8):698–704.
   PubMed Web of Science ®Google Scholar
• Rybak JM, Fortwendel JR, Rogers PD. Emerging threat of triazole-resistant Aspergillus fumigatus. J Antimicrob Chemother. 2019;74(4):835–842.
   PubMed Web of Science ®Google Scholar
• Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, et al. Triazole resistance in Aspergillus spp.: a worldwide problem? J Fungi (Basel). 2016;2(3):21.
   PubMedGoogle Scholar
• Gonzalez-Jimenez I, Lucio J, Amich J, et al. A Cyp51B mutation contributes to azole resistance in Aspergillus fumigatus. J Fungi (Basel). 2020;6(4):315.
   Google Scholar
• Liu W, Sun Y, Chen W, et al. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob Agents Chemother. 2012;56(5):2598–2603.
   PubMed Web of Science ®Google Scholar
• Paul RA, Rudramurthy SM, Meis JF, et al. A novel Y319H substitution in CYP51C associated with azole resistance in Aspergillus flavus. Antimicrob Agents Chemother. 2015;59(10):6615–6619.
   PubMed Web of Science ®Google Scholar
• Goncalves SS. Global aspects of triazole resistance in Aspergillus fumigatus with focus on Latin American Countries. J Fungi (Basel). 2017;3(1):5.
   Google Scholar
• Van Der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49(Suppl 1):S82–9.
   PubMedGoogle Scholar
• Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, et al. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008;52(4):1244–1251.
   PubMed Web of Science ®Google Scholar
• van der Torre MH, Novak-Frazer L, Rautemaa-Richardson R. Detecting Azole-Antifungal Resistance in Aspergillus fumigatus by Pyrosequencing. J Fungi (Basel). 2020;6(1):12.
   Google Scholar
• Scharmann U, Kirchhoff L, Hain A, et al. Evaluation of three commercial PCR assays for the detection of azole-resistant Aspergillus fumigatus from respiratory samples of immunocompromised patients. J Fungi. 2021;7(2):132.
   Web of Science ®Google Scholar
• van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis. 2011;17(10):1846–1854.
   PubMed Web of Science ®Google Scholar
• Resendiz-Sharpe A, Mercier T, Lestrade PPA, et al. Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. J Antimicrob Chemother. 2019;74(9):2759–2766.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Chowdhary A, Melchers WJ, et al. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362–368.
   PubMed Web of Science ®Google Scholar
• Koehler P, Hamprecht A, Bader O, et al. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. Int J Antimicrob Agents. 2017;49(2):218–223.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Verweij PE. Aspergillus fumigatus and pan-azole resistance: who should be concerned? Curr Opin Infect Dis. 2020;33(4):290–297.
   PubMed Web of Science ®Google Scholar
• Schauwvlieghe A, Buil JB, Verweij PE, et al. High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. Mycoses. 2020;63(2):122–130.
   PubMed Web of Science ®Google Scholar
• Aigner M, Lass-Florl C. Treatment of drug-resistant Aspergillus infection. Expert Opin Pharmacother. 2015;16(15):2267–2270.
   PubMed Web of Science ®Google Scholar
• Buil JB, Bruggemann RJM, Wasmann RE, et al. Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. J Antimicrob Chemother. 2018;73(1):134–142.
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89.
   PubMed Web of Science ®Google Scholar
• Schauwvlieghe A, Bredius RGM, Verdijk RM, et al. Management of cerebral azole-resistant Aspergillus fumigatus infection: a role for intraventricular liposomal-amphotericin B. J Glob Antimicrob Resist. 2020;22:354–357.
   PubMed Web of Science ®Google Scholar
• Gintjee TJ, Donnelley MA, Thompson GR. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi (Basel). 2020;6(1):28.
   PubMedGoogle Scholar
• Ghannoum M, Long L, Larkin EL, et al. Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis. Antimicrob Agents Chemother. 2018;62:e00244–18.
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Katragkou A, et al. Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1¡3)-β-D-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2020;64:e02429–19.
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G. Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins. J Fungi (Basel). 2020;6(4):262.
   PubMedGoogle Scholar
• Wiederhold NP, Najvar LK, Jaramillo R, et al. Extended-interval dosing of rezafungin against azole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother. 2019;63:e01165–19.
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi (Basel). 2020;6(4):239.
   PubMedGoogle Scholar
• Wiederhold NP. Review of the novel investigational antifungal olorofim. J Fungi (Basel). 2020;6(3):122.
   Google Scholar
• Kirchhoff L, Dittmer S, Buer J, et al. In vitro activity of olorofim (F901318) against fungi of the genus, scedosporium and rasamsonia as well as against Lomentospora prolificans, exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob Agents. 2020;56(3):106105.
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Sullivan SM, Smith LR, et al. Population pharmacokinetic modeling of VL-2397, a novel systemic antifungal agent: analysis of a single- and multiple-ascending-dose study in healthy subjects. Antimicrob Agents Chemother. 2019;63(6):e00163–19.
   PubMed Web of Science ®Google Scholar
• Mitsuyama J, Nomura N, Hashimoto K, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008;52(4):1318–1324.
   PubMed Web of Science ®Google Scholar